Value of PET-CT in Radiation Treatment Planning for Patients with Esophageal Cancer (RESPECT-shadow-study) - RESPECT-shadow

niversitair Medisch Centrum Groningen0 个研究点目标入组 130 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•-histological documented cancer of the esophagus or gastroesophageale junction (GEJ)
•- locally curable disease without distant metastases (M1b excluded)
•planned for high dose radiotherapy with or without chemotherapy
•- no previous or concurrent malignancy (except for basal cell ca. of the skin or in situ ca. of the cervix or superficial bladder ca. (pTa) in the past five years.
•- previously untreated patients (except induction chemotherapy)
•- no evidence of serious active infections
•- age >= 18 years
•- written informed consent to participate in the study
•- patients must have an WHO performance status 0-2
•- all patients must be evaluated by a radiation oncologist prior to enrollment to ensure that the patient is an appropriate candidate for radiation therapy.

•- known distant metastases
•- previous or concurrent malignancy (except for basal cell ca. of the skin or in situ ca. of the cervix or superficial bladder ca. (pTa) in the past five years
•- prior chest or upper abdominal radiotherapy, prior systemic chemotherapy, or prior esophageal or gastric surgery.
•- evidence of serious active infections
•- dementia or altered mental status that would prohibit the understanding and giving of informed consent
•-pregnant or lactating women. sexually active patients of childbearing potential must implement effective contraceptive practices during the study while in this study

发起方